Biocon sheds 4%, hits 52-week low as US FDA issues form 483 for 3 sites

The US health regulator has issued Form 483s with 11 observations each for two sites in Bengaluru and six observations for a plant in Malaysia site.

Biocon
SI Reporter Mumbai
3 min read Last Updated : Sep 01 2022 | 9:51 AM IST
Shares of Biocon hit a 52-week low of Rs 298.50 on slipping 3.6 per cent on the BSE in Thursday’s intra-day trade after US health regulator issued form 483s to the company with 11 observations each for its two sites in Bengaluru and six for a plant in Malaysia.

The stock was trading at its lowest level since April 2020. At 09:30 am; Biocon was quoting 2 per cent lower at Rs 303 vs a 1.2 per cent decline in the Sensex benchmark index. In the past three months, it has underperformed the market by falling 10 per cent as compared to a 5 per cent rally in the Sensex.

As per the US Food and Drug Administration (USFDA), Form 483 is issued at the conclusion of an inspection if an investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

The US Food and Drug Administration (US-FDA) conducted three on-site inspections at Biocon Biologics’ (company's subsidiary) seven manufacturing facilities spanning two sites in Bengaluru, India and one at Johor, Malaysia. These inspections started with the Bengaluru site on August 11, 2022 and concluded with the Malaysia site on August 30, 2022.

These inspections were initiated on account of three preapproval inspections for biosimilar Bevacizumab, rh-Insulin and Insulin Aspart and a capacity expansion inspection for biosimilar Trastuzumab. These included multiple drug substance and drug product facilities and other support infrastructure at these sites.

Biocon said that the company does not expect the outcome of these inspections to impact the current supply of its products. 

The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools to aid risk assessment & investigations and other procedural & facility upgrades, the company said.

“We will submit Corrective and Preventive Action Plans (CAPA), to the US FDA in the stipulated time frame,” Biocon said.

Biocon’s launches of bBevacizumab, bAspart and bAdalimumab, especially in the US, are expected to contribute to the near term growth of the business. With two strategic agreements signed with Serum and Viatris, Biocon is targeting revenues of $ 1.8 billion in FY24.

“We believe timely regulatory clearance and subsequent launch timeline, notably for expected FY23 launches of bAspart (CRL in September,2021) and bBevacizumab remain keys near term triggers for the company,” ICICI Securities said in a note.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Buzzing stocksBioconstock marketsMarkets

Next Story